研究概要
重组T细胞受体(TCR)的可溶性变体已成为有吸引力的工具,通过将其与CD3结合抗体结合在双特异性T细胞衔接器中,将细胞毒性T细胞重定向至细胞内肿瘤或病毒抗原;
中文摘要
可溶性重组T细胞受体(TCR)变体通过与CD3结合抗体结合形成双特异性T细胞衔接器,已成为将细胞毒性T细胞重定向至细胞内肿瘤或病毒抗原的有吸引力的工具;然而,基于TCR的NK细胞衔接器迄今尚未被研究。在此,我们利用二价IgG1样格式开发了基于TCR的双特异性制剂,用于重定向NK细胞。三功能NK衔接器包括一个增强与FcγRIII/CD16A结合的Fc部分,以及识别NKp46或CD16A的单链(scFv)抗体,后者为激活型NK细胞受体。包含亲和力成熟TCR和抗NKp46 scFv的HCMV pp65/HLA-A2反应性TCR-scFv-Fc融合蛋白以抗原特异性方式激活外周血NK细胞并诱导细胞毒性。对于T细胞重定向,TCR-scFv-Fc融合蛋白包含识别CD3ε的scFv抗体。与NK细胞衔接器相比,T细胞衔接器显示出相似的敏感性但较低的肽选择性。对于两种识别黑色素瘤相关肽的TCR,亲和力成熟的TCR-scFv-Fc融合蛋白能够实现NK和T细胞的重定向和激活,并杀伤负载外源性肽的肿瘤靶细胞。我们的结果扩展了可溶性TCR技术在NK细胞衔接器中的多功能性;然而,对于肽/MHC-I复合物密度较低的靶肿瘤细胞,其敏感性仍需改进。
展开英文摘要原文
Soluble variants of recombinant T cell receptors (TCRs) have become attractive tools for the retargeting of cytotoxic T cells toward intracellular tumor or viral antigens by combining them with CD3-binding antibodies in bispecific T cell engagers; however, TCR-based NK cell engagers have not been studied so far. Here, we developed TCR-based bispecific agents for the redirection of NK cells utilizing a bivalent IgG1-like format. Trifunctional NK engagers included an Fc part with enhanced binding to FcγRIII/CD16A and single-chain (scFv) antibodies recognizing either NKp46 or CD16A, activating NK cell receptors. HCMV pp65/HLA-A2 reactive TCR-scFv-Fc fusion proteins incorporating an affinity-matured TCR and anti-NKp46 scFv activated peripheral blood NK cells and induced cytotoxicity in an antigen-specific manner. For T cell redirection, TCR-scFv-Fc fusion proteins included an scFv antibody recognizing CD3ε. Compared with NK cell engagers, T cell engagers showed similar sensitivity but lower peptide selectivity. For two TCRs recognizing melanoma-associated peptides, affinity-matured TCR-scFv-Fc fusion proteins enabled NK and T cell redirection and activation, and killing of tumor target cells loaded with exogenous peptides. Our results expand the versatility of the soluble TCR technology to NK cell engagers; however, they still require improvement in sensitivity to target tumor cells with low peptide/MHC-I complex densities.
论文信息
- 作者
- Teschner AC、Gonçalves M、Meyer M、Zörnig I、Jäger D、Momburg F
- 单位
- Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.Germany
- 期刊
- Cells2026 Aug 27